drugset / Trial / NCT01697644

Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation

NCT01697644

Phase 4 Completed 75 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to assess and compare the efficacy and safety of two dose levels of somatropin over a long period (till final height is reached). This trial is an extension to trials GHRETARD/BDP/14/NL (a 2-year initial trial) and GHRETARD/BPD/20/NL (a 2-year extension trial).

Timeline

Start
1990-10
Primary completion
2005-05
Completion
2005-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 3 iu Subcutaneous
Subject Somatropin Protein / enzyme biologic 6 iu Subcutaneous